The potential role of the three-dimensional-bioprinting model in screening and developing drugs

doi:10.3748/wjg.v28.i47.6788

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 28, Issue 47

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3768)

All Articles published online

The chart showing PDF series, WORD series, HTML series.

Item

Count

PDF

245

WORD

HTML

2052

Sum=2338

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

396

Download

1038

Sum=1434

Dec 21, 2022 (publication date) through Mar 4, 2026

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Letter to the Editor

World J Gastroenterol. Dec 21, 2022; 28(47): 6788-6790
Published online Dec 21, 2022. doi: 10.3748/wjg.v28.i47.6788

The potential role of the three-dimensional-bioprinting model in screening and developing drugs

Bin Wu, Chao-Lin Deng

Chao-Lin Deng, Bin Wu, Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China

Author contributions: Wu B designed and revised the manuscript; Deng CL wrote the manuscript.

Supported by CAMS Innovation Fund for Medical Sciences, No. 2021-1-I2M-015, and National High Level Hospital Clinical Research Funding, No. 2022-PUMCH-B-003.

Conflict-of-interest statement: All authors declare that they have no conflicts of interest.

Corresponding author: Bin Wu, MD, PhD, Chief Doctor, Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 1 Shuaifuyuan Road, Wangfujing, Dongcheng District, Beijing 100730, China. wubin0279@hotmail.com

Received: October 15, 2022
Peer-review started: October 15, 2022
First decision: October 26, 2022
Revised: October 28, 2022
Accepted: December 5, 2022
Article in press: December 5, 2022
Published online: December 21, 2022
Processing time: 65 Days and 6.5 Hours

Abstract

Recently, we have read with great interest the original article used different spatial configuration models of colorectal cancer (CRC) for validating the anti-tumor efficacy with Diiminoquinone. We feel obliged to provide new insight into the drug screening models by integrating and analyzing the original method and result. These comments may provide comprehensive insights into three-dimensional drug screening models and the difference between pathologic subtypes in CRC.

Keywords: Colorectal cancer; three-dimensional-bioprinting; Mucinous adenocarcinoma; Drug screening models

Core Tip: Chemotherapy is the main treatment option for inoperable colorectal cancer (CRC). We recently read an article about the anti-cancer effects of Diiminoquinone. We feel obliged to express our opinion on this article on drug screening models and the difference between pathologic subtypes in CRC and hope it could deepen understanding for the reader.